Innovation Strategy for BioPharma: Proteomics for Optimal Selection of Preclinical Efficacy Models

May 21, 2024
11:30am EDT
Hosted Online

Drug Discovery is the foundation of the Pharma and Biotech effort to search for novel therapeutics that are safe and treat life-altering diseases. Pharma companies are continuously challenged to find ways to not only be more innovative, but also be more efficient and productive in their hunt for new efficacious drugs. This push for productivity, coupled with the increased complexity of therapeutic approaches and pressures to externalize portions of their discovery, has led to a change in the type of partnership a Pharma company needs when they search for a contract research organization (CRO) partner. What was once a more transactional discipline or study-specific model has evolved to one requiring a much closer partnership for executing larger drug discovery programs in a more integrated fashion. In turn, to successfully support integrated drug discovery programs, CROs not only need to have experienced scientists, but should also be organized similarly to their Pharma partner in order to access the required scientific disciplines in a combinatorial fashion (e.g., Pharmacology, DMPK, Bioanalysis, Biomarkers, and Toxicology).

In this webinar, we illustrate data and expertise-driven enhancement of inflammatory bowel disease (IBD) models with proteomic characterization of both human ulcerative colitis and two murine IBD models. Proteomic profiling identifies disease features that correlate with histology-based disease severity metrics and further distinguishes target and pathway differences that can provide a basis for matching a model to a therapeutic.

In this webinar, you will learn:

  • How the outsourcing model from pharma/biotech companies has evolved from routine commodity-based science to innovative, interdisciplinary drug discovery science.
  • The key pillars of a drug discovery program and the key questions that need to be addressed to successfully achieve goals and milestones.
  • Options for preclinical efficacy models in the areas of inflammatory bowel disease (IBD) and ulcerative colitis (UC).
  • How application of proteomic analysis to characterize disease pathways between murine IBD models can provide a better-informed basis for model selection.
  • How proteomic analysis of archival tissue provides protein system data to expand histology-based assessment of ulcerative colitis.

View the Conference Website



Schedule a Meeting

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now